TRU-SENTIMENT ยท DeltaNeutral
NKTR Trading Analysis - 11/06/2026 05:39 PM โ TRU-SENTIMENT
Options chain ยท Stock chart ยท Baseline chart
NKTR (Nektar Therapeutics) at $37.27. True Sentiment Bullish, delta 40-60 call 90% / put 10%, call $1,655,890 vs put $193,040. RSI 52.4.
- Symbol
- NKTR
- Price
- $37.27
- Article bias (separate from True Sentiment)
- neutral
- Conviction
- low
- Published
- 2026-11-06 17:39:00 ET
- Author
- DeltaNeutral staff
TRUE SENTIMENT ANALYSIS (DELTA 40-60 OPTIONS)
True Sentiment Analysis (Delta 40-60 Options):Options flow via True Sentiment (delta 40-60 only):
Call Volume: $1,655,890.00 (89.6%) Put Volume: $193,040.00 (10.4%) Total: $1,848,930.00
Sentiment: Bullish. Call contracts 1,412 vs put 139; call trades 34 vs put 26. Pure directional conviction strongly favors calls (89.6% dollar vol). This suggests near-term upside expectations despite bearish technicals. Divergence: Option spread engine reports "Divergence detected between technical indicators and options sentiment" with advice to wait for alignment.
Key Statistics: NKTR
Fundamental Snapshot
Valuation
| P/E (trailing) | 4.50 |
| EPS (trailing 12 mo) | $-2.87 |
| Market cap | $1.27B |
| Shares outstanding | 34.1M |
Dividend
| Dividend yield | 0.00% |
Risk & range
| Beta | 1.34 |
| 52-week low | $33.40 |
| 52-week high | $109.00 |
| Historical volatility | 90.8% |
Ownership & trading
| Institutional ownership | 45.4% |
| Average daily volume | 0.8M sh |
Reported figures; no analyst estimates.
๐ Analysis
News Headlines & Context:
The following recent context items for Nektar Therapeutics (NKTR) are provided from general knowledge and are separate from the data-driven analysis below:
- NKTR has been navigating a strategic pipeline shift, with recent focus on its immunology asset rezpegaldesleukin (REZPEG) and partner-dependent milestones.
- In late 2026, the stock experienced a sharp repricing lower after a clinical or commercial update triggered heavy volume selling (observed thematically around early October in the embedded price data).
- Biotech sector sentiment remained fragile amid rising rates and risk-off positioning, pressuring small-cap clinical-stage names.
- No confirmed near-term FDA catalyst was widely telegraphed; investors were monitoring cash runway and partnership developments.
- The embedded options data shows a bullish directional call lean despite weak technicals, possibly reflecting speculative positioning on a future catalyst.
Fundamental Analysis:
Based strictly on the provided FUNDAMENTALS data for NKTR:
| Metric | Value |
|---|---|
| Trailing P/E | 4.50 |
| Trailing EPS | -2.87 |
| Market Cap | 1,272,168,180.00 |
| Shares Outstanding | 34,143,000.00 |
| Dividend Yield | 0.00 |
| Beta | 1.34 |
| 52-Week High | 109.00 |
| 52-Week Low | 33.40 |
| Institutional Ownership | 45.41% |
| Average Volume | 790,000.00 |
| Historical Volatility | 90.78 |
Revenue growth, gross/operating/net margins, ROE, debt-to-equity, free cash flow, PEG ratio, forward P/E, and analyst target price are not available in the data (null). The negative EPS of -2.87 indicates the company is not profitable on a trailing basis. The low trailing P/E of 4.50 is distorted by negative earnings and is not a standard profitability-based valuation. Fundamentals show a clinical-stage profile with high volatility (90.78 historical) and moderate institutional holding (45.41%). This diverges from the bullish options sentiment but aligns with the bearish technical structure below.
Current Market Position:
Current price per indicators: $37.34. Recent daily action shows a decline from $60.40 (2026-09-28) to $37.34 (2026-11-06), with a 30-day range high of $62.40 and low of $35.61. Minute bars for 2026-11-05 to 2026-11-06 show opening at $38.36 (11-05) dropping to $36.20 close, then $36.58 open to $37.34 close on 11-06. Late session on 11-06 saw volume spikes: 51,513 at 15:50 and 49,656 at 15:55, with price dipping to $37.16 then recovering to $37.27. Intraday momentum is weak/choppy with no clear trend.
Technical Analysis:
Technical Indicators
SMA alignment: Price ($37.34) is below SMA 20 ($37.73) and far below SMA 50 ($51.95); SMA 5 ($37.29) is below SMA 20, confirming bearish structure. RSI at 52.37 is neutral, not oversold. MACD (-3.70) below signal (-2.96) with negative histogram (-0.74) shows bearish momentum. Bollinger mid $37.73, price inside lower half near $37.34; no squeeze signal. 30-day range: price at $37.34 is near lower third (low $35.61, high $62.40).
True Sentiment Analysis (Delta 40-60 Options):
Options flow via True Sentiment (delta 40-60 only):
Call Volume: $1,655,890.00 (89.6%) Put Volume: $193,040.00 (10.4%) Total: $1,848,930.00
Sentiment: Bullish. Call contracts 1,412 vs put 139; call trades 34 vs put 26. Pure directional conviction strongly favors calls (89.6% dollar vol). This suggests near-term upside expectations despite bearish technicals. Divergence: Option spread engine reports "Divergence detected between technical indicators and options sentiment" with advice to wait for alignment.
Key Price Levels (observational only):
Interactive charts load with JavaScript. This text is the crawlable summary.